Table 1 Immune cell density at baseline and after 2 weeks of anti-HER2 treatment according to baseline PAM50 intrinsic subtype.
Immune cell density at baseline | |||||
|---|---|---|---|---|---|
Immune cell Subpopulation | Immune cell density by intrinsic subtype: median (IQR) | ||||
Luminal A (N = 11) | Luminal B (N = 6) | HER2-enriched (N = 43) | Basal-like (N = 5) | p value | |
CD3+ | 781 (200–1035) | 1277 (696–1372) | 1073 (367–2313) | 644 (225–1921) | 0.419 |
CD8+ | 217 (77–383) | 461 (350–481) | 475 (125–1018) | 166 (64–648) | 0.562 |
CD4+ | 352 (84–445) | 525 (340–773) | 507 (151–1096) | 403 (144–502) | 0.374 |
Foxp3+ | 43 (13–93) | 28 (28–83) | 88 (45–202) | 52 (49–176) | 0.178 |
%Ki67+CD3+ | 6 (4–7) | 5 (3–8) | 9 (4–14) | 8 (5–17) | 0.178 |
%Ki67+CD4+ | 6 (4–10) | 7 (1–8) | 9 (4–13) | 9 (6–17) | 0.184 |
%Ki67+CD8+ | 5 (2–9) | 3 (3–7) | 8 (4–12) | 9 (5–19) | 0.188 |
%Ki67+Foxp3+ | 18 (14–20) | 15 (0–15) | 15 (9–18) | 19 (15–27) | 0.064 |
Immune cell density at day 15 | |||||
|---|---|---|---|---|---|
Immune cell subpopulation | Immune cell density by intrinsic subtype: median (IQR) | ||||
Luminal A (N = 7) | Luminal B (N = 6) | HER2-enriched (N = 33) | Basal-like (N = 3) | p value | |
CD3+ | 435 (193–747) | 749 (710–896) | 1669 (899–2461) | 1544 (501–1544) | 0.008 |
CD8+ | 296 (66–367) | 442 (405–492) | 769 (481–1417) | 583 (275–583) | 0.007 |
CD4+ | 204 (102–322) | 272 (228–295) | 713 (361–1136) | 629 (158–629) | 0.011 |
Foxp3+ | 44 (13–48) | 37 (22–39) | 214 (93–300) | 195 (46–195) | 0.004 |
%Ki67+CD3+ | 3 (2–3 | 1 (1–1) | 4 (2–7) | 7 (3–7) | 0.051 |
%Ki67+CD4+ | 3 (3–3) | 1 (1–2) | 5 (2–7) | 10 (5–10) | 0.062 |
%Ki67+CD8+ | 2 (1–2) | 1 (1–1) | 3 (2–8) | 6 (2–6) | 0.058 |
%Ki67+Foxp3+ | 7 (5–13) | 2 (1–9) | 7 (3–12) | 15 (5–15) | 0.412 |
